Biotechnology
Agilent and National University of Singapore Launch Center of Excellence in Cell Metabolism to Improve Population Health
Center will enable targeted and untargeted metabolic profiling for
population-based large-scale cohorts across translational research
SINGAPORE, Oct. 4, 2024 /PRNewswire/ -- Agilent Technologies Inc.
2024-10-04 09:00
2796
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...
2024-10-04 04:00
2902
The Exosome Production Method Patent by Panacell Biotech Registered as Original Technology
SEOUL, South Korea, Oct. 3, 2024 /PRNewswire/ -- Panacell Biotech Co., Ltd. (Panacell Biotech) announced that the patent related to their exosome manufacturing method filed last year was registered as a core technology in the patent registry onAugust 7, 2024, following the Patent Act. Panacell B...
2024-10-03 20:00
1737
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR),Singapore's lead publ...
2024-10-03 09:00
1962
South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika
* SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure. * The company aims to double sales of IDT Biologika by 2028 through new business projects and operational efficiency. ...
2024-10-02 20:00
2081
PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c Agonist)
TOKYO, Oct. 1, 2024 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo; President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called "FGF2 alternative peptide (FGFR1c agonist)", which has equivalent function to recombinant FGF2 (Fibroblast Growth Factor 2, ...
2024-10-01 21:00
1475
Precision Medicine Group Welcomes Margaret Keegan as CEO
-- Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors -- BETHESDA, Md., Oct. 1, 2024 /PRNewswire/ -- Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, to...
2024-10-01 20:49
1387
Frost & Sullivan co-published Recombinant Type III Triple-Helix Collagen Whitepaper with Everon Healthcare
SHANGHAI, Oct. 1, 2024 /PRNewswire/ -- Frost & Sullivan and Everon Healthcare have conducted extensive investigation across the recombinant collagen Industry and co-published the "Recombinant Type III Triple-Helix Collagen Whitepaper" on Sep. 29th, 2024, which aims to analyze the latest research a...
2024-10-01 17:28
1931
Great Place To Work® Australia and New Zealand names 15 Best Workplaces in Healthcare, Biopharma & Social Assistance in 2024
SYDNEY, Oct. 1, 2024 /PRNewswire/ -- Great Place To Work® ANZ, the global authority on workplace culture today announces theirinaugural 15 Best Workplaces™ in Healthcare, Social Assistance and BioPharma in 2024. The companies are announced across two lists: Best Workplaces in Biotechnology a...
2024-10-01 07:00
8123
GenEditBio Secures Strategic Investment from Gobi Partners GBA to Accelerate Breakthrough Genome Editing Technologies
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a biotech company co-founded by Prof. ZHENG Zongli from the CityUniversity of Hong Kong that focuses on precision genome editing to provide affordable "precision DNA surgery" for genetic diseases with unmet needs, is ple...
2024-09-30 19:36
1864
NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics
Scalable and adaptable, TETRIS captures the diversity of protein interactions
on site to inform accurate cancer diagnoses, enabling the personalisation of
ensuing treatments.
SINGAPORE, Sept. 30, 2024 /PRNewswire/ -- A team of researchers from the
National University of Singapore's
2024-09-30 15:51
1456
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...
2024-09-30 15:00
1098
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- OnSeptember 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr.Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along with leading Chinese onco-h...
2024-09-30 13:48
1063
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA) for a new indication: cadonilimab in combination with...
2024-09-30 13:42
1021
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
* Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of$850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire...
2024-09-30 13:00
980
SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approv...
2024-09-29 21:00
1336
IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentati...
2024-09-29 21:00
2243
Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held inXiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront o...
2024-09-29 11:52
2608
New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building atShanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for...
2024-09-28 20:00
3117
Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going global and analyzes the driving forces behind their accelerated global expa...
2024-09-28 09:11
3346
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 303 media titles]
2024-12-27 13:17
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 253 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 245 media titles]
2024-12-25 15:45Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
[Picked up by 239 media titles]
2024-12-27 11:24
